Literature DB >> 10661873

Characterization of a new member of the TNF family expressed on antigen presenting cells.

C Tribouley1, M Wallroth, V Chan, X Paliard, E Fang, G Lamson, D Pot, J Escobedo, L T Williams.   

Abstract

The TNF family is involved in the regulation of the immune system, and its members have been implicated in a variety of biological events such as apoptosis, cell proliferation, differentiation and survival. Here we present a new member of the TNF family, tumor necrosis factor superfamily member 20 (TNFSF20) that we have identified from the expressed sequence tag (EST) database and characterized. The human protein is a 285 amino acid long type II transmembrane protein and is 19% homologous to TNF in its extra-cellular domain. TNFSF20 is expressed at the surface of antigen presenting cells such as cells of the macrophagemonocyte lineage and dendritic cells. After treatment with bacterial lipopolysaccharide (LPS), TNFSF20 expression is downregulated at the surface of the expresssing cells, suggesting that the membrane-bound protein gets cleaved, and that a soluble factor is released in the extra-cellular compartment. The soluble form of the recombinant TNFSF20 induces proliferation of resting peripheral blood monocytes (PBMC) and cell death of activated lymphocytes. TNFSF20 might therefore play a critical role in the regulation of cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10661873     DOI: 10.1515/BC.1999.186

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  16 in total

1.  Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice.

Authors:  Anshu Marathe; Suhasini Iyer; Zhihua Julia Qiu; Jennifer Visich; Donald E Mager
Journal:  Pharm Res       Date:  2012-07-18       Impact factor: 4.200

2.  Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.

Authors:  Xiaoxia Wen; Mi-Ae Lyu; Rui Zhang; Wei Lu; Qian Huang; Dong Liang; Michael G Rosenblum; Chun Li
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

3.  Mutational analysis of human BLyS in patients with common variable immunodeficiency.

Authors:  Claretta Gioia Losi; Ulrich Salzer; Roberta Gatta; Vassilios Lougaris; Gemma Cattaneo; Antonella Meini; Annarosa Soresina; Bodo Grimbacher; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2006-06-01       Impact factor: 8.317

4.  Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF.

Authors:  Chaim O Jacob; Luminita Pricop; Chaim Putterman; Michael N Koss; Yi Liu; Maria Kollaros; Sarah A Bixler; Christine M Ambrose; Martin L Scott; William Stohl
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

5.  The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors:  William Stohl; David M Hilbert
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

Review 6.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

7.  Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity.

Authors:  William Stohl; Noam Jacob; William J Quinn; Michael P Cancro; Huaxin Gao; Chaim Putterman; Xiaoni Gao; Luminita Pricop; Michael N Koss
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

8.  Apoptosis in autoimmune diabetes: the fate of beta-cells in the cleft between life and death.

Authors:  Charles Sia; Arno Hänninen
Journal:  Rev Diabet Stud       Date:  2006-05-10

9.  Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.

Authors:  M Schaller; W Stohl; S M Tan; V M Benoit; D M Hilbert; H J Ditzel
Journal:  Ann Rheum Dis       Date:  2004-09-30       Impact factor: 19.103

10.  Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus.

Authors:  W Stohl; S Metyas; S-M Tan; G S Cheema; B Oamar; V Roschke; Y Wu; K P Baker; D M Hilbert
Journal:  Ann Rheum Dis       Date:  2004-09       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.